Oncology
ASCO 2023

ASCO 2023 – Gregory Lubiniecki

With its blockbuster checkpoint inhibitor Keytruda, Merck has been a star of the show at many ASCO conferences in recent years.

Oncology
ASCO 2023

ASCO 2023 – Arun Krishna

With a 51% reduction in deaths, AstraZeneca’s ADAURA trial was one of the breakout stories of this year’s ASCO.

R&D
Health Innovators Jennifer Schranz

Health Innovators – Jennifer Schranz

In the rare and ultra-rare disease space, the paucity of both data and patients makes everything about research and development more complicated.

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Patients

R&D